Zimmer Biomet Spine Marks New Mobi-C Cervical Disc Milestone

Zimmer Biomet Spine has announced that more than 150,000 Mobi-C Cervical Discs have been implanted worldwide.

Zimmer Biomet holds a commanding position in the $200 million global cervical disc market, according to the company. The Mobi-C device represents an optimal solution with statistical superiority to two-level fusion at seven years.

James Cloar, President of Zimmer Biomet Spine, noted, “Mobi-C is supported with great, long-term clinical data and we are proud to announce this milestone that highlights its market success, as well.”

“The availability of the Mobi-C artificial disc has helped surgeons give patients the best opportunity to maintain motion and avoid a fusion. This leads to faster return to work and lower rates of adjacent level disease,” added Dr. Michael Hisey, board-certified orthopedic surgeon at Texas Back Institute who was a participant in the Investigational Device Exemption study. “With the Mobi-C one step insertion and mobile core technology, I have a disc that allows me to operate with a familiar technique and I know that the disc motion will adapt to patients with a variety of cervical conditions.”

The Mobi-C Cervical Disc was first implanted in France in 2004 and was approved for sale in the United States by the U.S. Food and Drug Administration (FDA) in 2013.

Mobi-C is the first cervical disc prosthesis approved by the FDA for reconstruction of a cervical disc at both one and two levels (C3-C7). Mobi-C is a cobalt chromium alloy and polyethylene mobile-bearing prosthesis that is inserted in a single step, without requiring bone chiseling or other vertebral anchorage such as screws or keels. The Mobi-C Cervical Disc Prosthesis is indicated in skeletally mature patients for reconstruction of the disc from C3-C7 following discectomy at one level or two contiguous levels for intractable radiculopathy (arm pain and/or neurological deficit) with or without neck pain or myelopathy due to abnormality localized to the level of the disc space and at least one of the following conditions confirmed by radiographic imaging (CT, MRI or X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes) and/or visible loss of disc height compared to adjacent levels. The Mobi-C Cervical Disc Prosthesis is implanted using an anterior approach. Patients should have failed at least six weeks of conservative treatment or demonstrated progressive signs or symptoms despite nonoperative treatment prior to implantation of the Mobi-C Cervical Disc Prosthesis.